Clinical Trial

Desloratadine as Adjunct Therapy for Rheumatoid Arthritis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease. The purpose of this study is to evaluate the effectiveness and safety of adding desloratadine to standard therapy in patients with active rheumatoid arthritis. Participants will receive either desloratadine or placebo in addition to their usual treatment. The study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether desloratadine could be a useful add-on treatment option for patients with rheumatoid arthritis.
Trial Details
NCT Number NCT07632872
Lead Sponsor Horus University
Conditions Rheumatoid Arthritis (RA), Rheumatoid Arthritis
Enrollment 60 participants
Start Date 2026-05-23
Primary Completion 2026-11 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08